Stocks Health care TNDM
NASDAQ · Health careTandem Diabetes Care Inc (TNDM)
Tandem Diabetes Care Inc brought in $1.1B of revenue over the twelve months to September 30, 2026, up 6.8% from a year earlier. It posted a net loss of $49.2M. In fiscal 2025 capital spending exceeded operating cash flow by $29.7M. At September 30, 2026 it held $72.8M in cash against $603.4M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Tandem Diabetes Care Inc
- Net worth
- Tandem Diabetes Care Inc has a market value (market cap) of $1.3B at the latest share price, and shareholders' equity of $135.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $1B (+7.9% year on year), with a net loss of $204.7M. Over the 12 months to September 30, 2026: revenue $1.1B, net loss $49.2M.
- Cash flow
- In fiscal 2025 operations used $9.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Tandem Diabetes Care Inc's next report is expected around February 18, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Tandem Diabetes Care Inc does
Tandem Diabetes Care Inc is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker TNDM.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1B | -$204.7M | -$3.04 | -$29.7M |
| 2024 | $940.2M | -$96M | -$1.47 | $5M |
| 2023 | $747.7M | -$222.6M | -$3.43 | -$58.6M |
| 2022 | $801.2M | -$94.6M | -$1.47 | $16.4M |
| 2021 | $702.8M | $15.6M | $0.24 | $97.2M |
| 2020 | $498.8M | -$34.4M | -$0.56 | -$2.7M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where TNDM ranks in Health care
Latest SEC filings
What Tandem Diabetes Care Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Passive stake (5% or more) SCHEDULE 13G
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 14% to $283.7M versus the same quarter last year; diluted EPS -$0.10 versus -$0.31.
- November 5, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 5.8% to $254.6M versus the same quarter last year; diluted EPS -$0.31 versus -$0.78.
- August 6, 2026
- May 28, 2026
- May 27, 2026
- May 21, 2026
- May 15, 2026
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 5.5% to $247.2M versus the same quarter last year; diluted EPS -$0.30 versus -$1.97.
Insider trades
What the people running Tandem Diabetes Care Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $32.6K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 27, 2026 | Twomey Christopher JDirector | Exercised options | 1,700 | $32.3K |
| October 27, 2026 | Twomey Christopher JDirector | Soldpre-planned (10b5-1) | 1,700 | $32.6K |
| October 15, 2026 | Kyrillos Jean-ClaudeEVP & Chief Operating Officer | Exercised options | 3,637 | - |
| October 15, 2026 | Kyrillos Jean-ClaudeEVP & Chief Operating Officer | Shares withheld for tax | 1,926 | $31.8K |
| August 15, 2026 | Hansen Shannon MarieEVP & Chief Legal Officer | Exercised options | 1,097 | - |
| August 15, 2026 | Hansen Shannon MarieEVP & Chief Legal Officer | Shares withheld for tax | 559 | $12.7K |
| August 15, 2026 | Hansen Shannon MarieEVP & Chief Legal Officer | Exercised options | 1,917 | - |
| August 15, 2026 | Hansen Shannon MarieEVP & Chief Legal Officer | Shares withheld for tax | 976 | $22.2K |
Who owns TNDM
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Sessa Capital (Master), L.P.13G, passive with 4 related filers | 6.71% | May 15, 2025 |
| Vanguard Portfolio Management13G, passive | 5.91% | April 29, 2026 |
| The Goldman Sachs Group, Inc.13G, passive with 1 related filers | 5.9% | November 9, 2026 |
| Vanguard Capital Management13G, passive | 5.18% | April 30, 2026 |
Largest institutional holders
Insiders
16 insiders reported holding 636,475 shares in total, about $11.6M at the last price.
| Holder | Shares |
|---|---|
| Sheridan John FPRESIDENT & CEO, Director | 160,260 |
| Morrison SusanEVP & Chief Admin. Officer | 52,788 |
| Vosseller LeighEVP & CHIEF FINANCIAL OFFICER | 52,040 |
| Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER | 40,317 |
| Gasser Elizabeth AnneEVP, Chief Strategy Officer | 34,50533,109 held indirectly |
| Carpenter RickEVP & Chief Technology Officer | 32,148 |
| Kyrillos Jean-ClaudeEVP & Chief Operating Officer | 32,001 |
| Hansen Shannon MarieEVP & Chief Legal Officer | 31,650 |
| Howell Peyton RDirector | 29,836 |
| Allen DickChair Emeritus | 28,146 |
Questions about TNDM
What does Tandem Diabetes Care Inc do?
Tandem Diabetes Care Inc is a company in the Health care sector, listed on NASDAQ as TNDM. Its shares trade on NASDAQ under the ticker TNDM.
What is Tandem Diabetes Care Inc's net worth?
Tandem Diabetes Care Inc has a market value (market cap) of $1.3B at the latest share price, and shareholders' equity of $135.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Tandem Diabetes Care Inc profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $49.2M on revenue of $1.1B.
How much revenue does Tandem Diabetes Care Inc make?
Over the twelve months to September 30, 2026 Tandem Diabetes Care Inc reported revenue of $1.1B. That is 6.8% more than a year earlier.
When did Tandem Diabetes Care Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from November 9, 2026.
When is Tandem Diabetes Care Inc's next earnings report?
Tandem Diabetes Care Inc's next report is expected around February 18, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare TNDM with
Follow TNDM
Get an email when Tandem Diabetes Care Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Tandem Diabetes Care Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.